Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exploiting Unsold Rams: May Be Less expensive Than You Suspect - 2Doomed SpaceX Starlink satellite photographed from orbit
- 3I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- 4Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 5Instructions to Pick the Ideal SUV Size for Seniors
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- Finding Your Motivation: Moves toward a Satisfying Life
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- 6 Famous kind of practice on the planet
- Allow Innovative Progressions To have a Tremendous Effect
- The Best Internet based Retailers for Style and Frill
- An Investigate of 6 Creative Specialty Mixed drinks
